Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 25, Issue 5, Pages 567-620Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881110391123
Keywords
Antipsychotics; evidence-based guidelines; relapse prevention; schizophrenia; treatment
Funding
- Bristol-Myers Squibb
- Janssen
- Lilly
- Schering Plough
Ask authors/readers for more resources
These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving experts in schizophrenia and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from the participants and interested parties, and cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. The practice recommendations presented are based on the available evidence to date, and seek to clarify which interventions are of proven benefit. It is hoped that the recommendations will help to inform clinical decision making for practitioners, and perhaps also serve as a source of information for patients and carers. They are accompanied by a more detailed qualitative review of the available evidence. The strength of supporting evidence for each recommendation is rated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available